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Abstract: Herein we report for the first time Carbonic Anhydrase Inhibitors (CAIs) of the 
sulfonamide, sulfamate and coumarin classes bearing the phenylureido tail from the clinically used 
drug Sorafenib, a multikinase inhibitor actually used for the management of hepatocellular 
carcinomas. All the final compounds were assayed on human (h) expressed CA isoforms I, II, VII 
and IX and showed quite interesting kinetic profiles. Among the sulfonamide ones, compounds 14-
16 and 26 were selective in inhibiting the hCA IX with KI values in the low nanomolar ranges (i.e. 
0.7-30.2 nM). We explored the binding modes of such compounds by means of X-ray crystallographic 
studies on the hCA I in adduct with the sulfonamide 16 and a sulfamate 21. Moreover, we 
antiproliferative properties of less investigated sulfamates 23 and 24 on breast tumor cell lines were 
investigated. 
Keywords: Carbonic Anhydrase, Sorafenib, Carbonic Anhydrase Inhibitors, sulfonamide, sulfamate, 
coumarin 
  
1.Introduction 
The 15 human (h) expressed Carbonic Anhydrases (CAs, EC 4.2.1.1) are zinc (II) dependent 
metalloenzymes, differently distributed at subcellular and tissue level [1,2]. hCAs are involved in 
vital physiological reactions by means of the reversible conversion of carbon dioxide to bicarbonate 
and protons [3]. Abnormalities in hCA expressions usually result in diseases, such as hypertension, 
glaucoma, epilepsy, obesity and altitude sickness and cancers [3,4]. Carbonic anhydrase inhibitors 
(CAIs) of the sulfonamide type or their bioisosteres, are routinely used as drugs. The most used are 
Acetazolamide (AAZ), methazolamide (MTZ), dichlorophenamide (DCP), brinzolamide (BRZ), 
Sulthiame (SLT), Zonisamide (ZNS), the sulfamate Topiramate (TPM) and various COXIBs with 
dual CA-cycloxygenase activity such as Celecoxib and Polmacoxib [3,5]. Besides the sulfonamide 
moiety, many new types of CAIs acting as zinc binders were validated (i.e. dithiocarbamates [6–9] 
xanthates [10] and monothiocarbamates [11]). In addition new moieties include molecules able to 
interact to the zinc coordinated water/hydroxide ion (i.e. phenols [12–16], carboxylic acids [16,17], 
polyamines [18,19], thiooxycoumarins [20,21] and the sulfamic acid group from hydrolysis of 
sulfocoumarins [22–28]), compounds occluding the entrance of the CA active site (cinnamic acid 
derivatives from in situ hydrolyzed coumarins [20,29–32]) and out of the site CAIs such as the 2-
(benzylsulfonyl)-benzoic acid [33]. Although many CAI chemical moieties were reported, the 
selectivity in targeting specific enzymatic isoforms was not granted. Therefore, any medicinal 
chemistry application of CAIs resulted hampered. Interestingly, the decoration of the CAI warhead 
by means of appropriate tails revealed to be a valid strategy to overcome the lack of enzymatic 
selectivity. In particular the arylureido-tails were particularly efficient in solving the selectivity issue 
among the hCA isoforms [34], and in particular such a moiety revealed preferential inhibition towards 
the tumor associated isoforms (i.e. hCAs IX and XII) over the cytosolic off-target ones (i.e. hCAs I 
and II) in vitro. Such results were confirmed in in vivo experiments using an appropriate breast cancer 
model [32, 33], and it was rationalized at molecular level by using X-ray crystallography techniques. 
The flexibility of the ureido-group is claimed responsible in allowing the entire molecule to better fit 
within the CA active site, and thus in maximizing the interactions occurring between the ligand and 
the amino acid residues exposed at the enzymatic cleft [35, 37]. The compound (4-(3-(4-
fluorophenyl)ureido)benzenesulfonamide, also known as SLC-0111, was obtained by application of 
such a strategy and currently is facing phase II clinical trials in combination with gemcitabine for the 
treatment of metastatic pancreatic ductal cancer [38]. SLC-0111 is selective inhibitor of the hCA IX 
isoform which has almost exclusive expression in hypoxic tumors [39–41], and is mainly responsible 
of the extracellular pH modulation [36, 39–41]. A recent application of the ureido tail strategy was 
reported by our group in the literature with ureido- substituted sulfamates, coumarins, 4-hydroxy-3-
(3-(phenylureido)benzenesulfonamides, N'-phenyl-N-hydroxyureas and N-aryl-N’-ureido-O-
sulfamates [20,42–46].  
Our pursuit to find more efficient ureido-bearing molecules to treat hypoxic tumors directed us to 
Sorafenib (Nexavar®), an orally available multikinase inhibitor approved by FDA to treat 
hepatocellular carcinoma (HCC). Clinical studies showed Sorafenib to exert promising effects on 
thyroid cancer, myeloid leukemia, mesothelioma and prostate cancers [47]. HCC is one of the most 
common cancers associated to high ratio of mortality [48,49,47]. Sorafenib was proved to extend a 
median time of progression in patients with advanced HCC and life span of patients with an average 
of three months [50, 52].  
 
2. Results and Discussion 
2.1. Drug Design and Chemistry. 
In light of our discoveries on arylureido containing molecules for the management of hypoxic 
cancers, we decided to merge the structures of Sorafenib and SLC-0111 to obtain a novel series of 
CAIs potentially useful to manage such types of pathologies, as schematically represented in Figure 
1. 
 
Figure 1. Sorafenib, SLC-0111 and 13 obtained by our synthetic strategy. 
 
Our design strategy was further extended to include series of compounds bearing the 
sulfonamides, the sulfamates and the coumarin CAIs warhead.  
As reported in Schemes 1-3, final compounds 12-17 and 21 were easily obtained by coupling the 
amino containing materials 1-6 and 10 with the commercially available 4-chloro-3-
(trifluoromethyl)phenyl isocyanate 11. The same reaction was applied to the synthesis of 
intermediates 18-20. In particular 18 and 19 were further decorated with the sulfonamide bioisosteres 
sulfamate moiety to afford 23 and 24 (scheme 2), whereas the latter 20 was activated by means of its 
NHS ester 25 which was used to obtain elongated CAIs of the sulfonamide (i.e. 26, 27, 29, 31) [51] 
and of the coumarin type (i.e. 33 and 35) [32].  
 
Scheme 1. General synthesis of ureido derivatives 12-21 
 
 
Scheme 2. General synthesis of sulfamates 23-24 
 
Figure 3. General synthesis of carbamides 26-27, 29, 31, 33, 35: 
All compounds were characterized by means of 1H-, 13C-, 19F-NMR and ESI mass 
spectroscopy techniques.  
2.2. Carbonic Anhydrase Inhibition 
The reported compounds having the sulfonamides (i.e. 12-17, 26, 27, 29, 31), the sulfamates (i.e. 23, 
24) and the coumarin (i.e. 21, 33, 35) moieties  were tested in vitro for their inhibitory properties 
against the physiologically relevant hCA isoforms hCA I, II, VII, IX in comparison with Sorafenib 
and the clinically used drug Acetazolamide (AAZ) by means of the stopped-flow carbon dioxide 
assay [52] (Table 1).  
 
 
      KI (nM)* 
Cmp   hCA I   hCA II   hCA VII  hCA IX 
 
12   0.63   0.24   0.38   0.13  
13   84.5   1.8   198.5   3.9  
14   6422.9   71.5   916.3   1.8  
15   4042.3   744.5   893.0   30.2  
16   513.6   51.4   801.2   0.7  
17   913.4   385.6   911.3   3972  
21   >10000  >10000  >10000  1588.1  
23   48.7   3.7   5.7   1.3 
24   39.3   4.0   3.5   0.8  
26   432.1   90.0   210.1   4.2  
27   4545.1   2660.2   488.1   3298  
29   4601.0   932.9   363.3   188.3  
31   6348.3   5761.4   584.9   102.4  
33   >10000  >10000  >10000  3412.4  
35   >10000  >10000  >10000  2254.4  
Sorafenib  >10000  >10000  8136.4   >10000 
SLC-0111**  5080   960   8550   45.1 
AAZ   250.0   12.1   6.0   25.8  
 
* Mean from 3 different assays, by a stopped flow technique (errors were in the range of  5-10 % of 
the reported values). ** From reference [35, 53] 
 
The inhibition data are showed in Table 1 and the following SARs are below discussed: 
(i) The off target cytosolic isoform hCA I was inhibited by all compounds with zinc binding 
properties 12-17, 23-24, 26-27, 29, 31 with a variety of potencies. The derivative of 
acetazolamide 12 acted as sub-nanomolar hCA I inhibitor with a KI of 0.63 nM. Sulfanilamide 
derivative 13 and two sulfamates 23-24 were potent hCA I, possessing inhibition constants 
ranging between 39.3 to 84.5 nM. Remaining compounds were medium potency hCA I 
inhibitors, they act as more potent inhibitors compare to acetazolamide AAZ (KI of 250 nM). 
Remaining sulfonamides showed a lower affinity for hCA I, with KIs in the range of 432.1-
6422.9 nM. The coumarins 21, 33, 35 did not inhibit the slow cytosolic isoform (hCA I) with 
inhibition constants > 10 µM. This result has been observed before by many coumarin 
derivatives [20,29–31].  
(ii) The second abundant cytosolic isoform hCA II was inhibited by sulfonamides and sulfamates 
with KIs in a range of 0.24-5761.4 nM. Compounds 12-13 and 23-24 acted as potent hCA II 
inhibitors with KIs of 0.24-4.0 nM. AAZ derivative 12 was the most potent inhibitor of 
cytosolic isoform hCA II with a KI of 0.24 nM, the second most potent inhibitor was 
sulfanilamide derivative 13 with a KI of 1.8 nM. Two sulfamates 23-24 also acted as potent 
inhibitor of this isoform with KIs of 3.7 and 4.0, respectively. Remaining sulfonamide 
derivatives 14-17 were from medium to less potent inhibitors of this hCA isoform with variety 
of KIs between 51.4-744.5 nM. We observed a dramatic change of KI (39.7 fold) by switching 
sulfonamide group from para- position 13 to meta- position 14 which had an inhibition 
constant of 71.5 nM. When a hydroxy group was appended at the para- position towards the 
sulfonamide of 14 to afford 15, the inhibition constant (KI) lowered to 744.5 nM (10.4 fold). 
Very recently we investigated inhibition properties of ureido- derivatives of 4 which are same 
chemotype of 15 which were also weak inhibitors of hCA II isoform [44]. The introduction 
of aliphatic linker between the ring bearing zinc binding group (ZBG) and urea group (16-17) 
was showed to lower hCA II inhibitory properties, with KIs 51.4 for 16 and 385.6 for 17 (28.6, 
214.2 fold, respectively compared to 13). When a benzamide group was inserted in between 
the phenylureido tail and inhibitor heads to investigate inhibition properties of longer 
compounds, 26-27, 29, 31. These compounds were weak inhibitors of hCA II isoform with 
KIs in range of 90-5761 nM. We previously obtained the X-Ray crystal structures of ether 
tailed sulfonamides whose tails were located at the outer rim of active site of hCA II [51]. It 
is reasonable to hypothesize that compounds 29, 31 have similar behavior. The coumarins 21, 
33, 35 did not inhibit the slow cytosolic isoform (hCA I) with inhibition constants > 10 µM. 
This result has been observed before by many coumarin derivatives. 
(iii) Compounds investigated here also showed a variety of different inhibition constants on 
cytosolic isoform hCA VII. The sulfonamides and the sulfamates were inhibited the hCA VII 
with KIs in the range of 0.38-916.3 nM. Again, acetazolamide derivative 12 was the most 
potent inhibitor with a KI of 0.38 nM. Followed by two potent sulfamates 23-24 with KIs 5.7, 
3.5 nM, respectively. These three compounds were acted as more effective inhibitors compare 
to AAZ (KI of 6 nM). Remaining compounds were weak inhibitors of hCA VII isoform KIs 
in the range of 198.5-916.3 nM. The coumarins did not inhibit cytosolic isoform VII as well 
with KIs > 10 µM. 
(iv) Sulfonamides and sulfamates reported here were effective as medium potency inhibitors of 
tumor associated extracellular isoform hCA IX with KIs ranging 0.13-3972 nM. 12-16, 23-24, 
26 showed excellent CA IX inhibitory profiles with KIs in the range of 0.13-30 nM. 29 and 
31 were weak inhibitors of this isoform with KIs of 188.3 and 102.4 nM, respectively. Two 
sulfonamide derivatives 17 and 27 were ineffective inhibitors with KIs of 3972 and 3298 nM, 
respectively. Coumarin derivatives 21, 33 and 35 were also poorly inhibited tumor associated 
isoform hCA IX (KIs of 3972 to 3412.4 nM). AAZ derivative 12 was again a sub-nanomolar, 
most potent inhibitor of the series with a KI of 0.13 nM and again more potent inhibitor 
compare to AAZ (KI of 25.8 nM). Followed by 16 which is also a sub-nanomolar inhibitor of 
this isoform (KI of 0.7 nM). Insertion of an ethyl- group instead of methyl- between the ureido 
linker and sulfonamide possessing phenyl ring dramatically decreased inhibitory profile, 17 
showed ineffective inhibitory profile (5674.29-fold). Whereas, deletion of the methyl group 
results 13 (the derivative of SLC-0111) in 5.6-fold weaker inhibitory of this isoform (KI of 
3.9 nM). Manipulation of the sulfonamide group from 4-position to 3-position has enhanced 
the inhibitory profile 2.16-folds 14 (KI of 1.8 nM). Whereas an insertion of -OH group at para 
position of Sulfonamide at 14 gives 15 that showed dramatic decrease of inhibition of this 
isoform 16.78-fold (30.2 nM). Two sulfamates 23-24 were excellent inhibitor of this isoform 
with KIs of 1.3 and 0.8 nM, respectively. This results were obtained previously ureido-
possessing sulfamates [54]. To obtain longer inhibitor molecules a phenylcarbamate moiety 
was inserted between the ureido- tail and inhibitor heads to obtain 26-27, 29 and 31. The 
methylene benzenesulfonamide head possessing derivative 26 showed excellent inhibitory 
effect with a KI of 4.2 nM whereas ethylbenzenesulfonamide derivative 27 was ineffective 
inhibitor with a KI of 3298 nM, that shows a dramatic change by addition of methyl group. 29 
and 31 were medium potency inhibitors with KIs of 188.3 and 102.4 nM, respectively. 
Coumarins 21, 33, 35 inhibited transmembrane isoform with low efficiency (KIs 1.59-4.31 
µM), whereas did not inhibit any of cytosolic isoforms (CA I, II, VII), (Table 1). 
Overall the kinetic data showed a preferential inhibition of the sulfonamide and sulfamate compounds 
on the hCA IX isoform with a  
 
2.3. X-Ray crystallography. 
We assessed the binding modes of compounds 17 and 23 within the active site of hCA I by 
means of X-ray crystallographic experiments. Our intention was to investigate a hCA isoform usually 
less considered since the majority of CA X-ray crystal adducts reported are related to the ubiquitous 
hCA II or to the tumor associated hCA IX mimic [16]. hCA I is abundant in red blood cells (at 1 µM 
concentration level), and it might influence the pharmacokinetics of drugs interacting with it or other 
CA isoforms of pharmacological interest. 
The difference |Fo Fc| electron density maps showed well ordered structures within the active 
site of hCA I and clearly assignable to compounds 17 and 23 bounded by means of their sulfonamide 
and sulfamate group to the protein metal ion (Figure 3).  
 
Figure 2. hCA I complexes of compound 17 (A; PDB accession code 6I0L) and 23 (B; PDB accession 
code 6I0J) at 1.4 and 1.35 Å resolution respectively. 
 
A deep look into the structural features revealed 17 and 23 coordinated to the Zn (II) ion by 
means of the deprotonated sulfonamide and sulfamate moieties (SO2NH
-, OSO2NH
-), which in turn 
are also involved in a strong H-bond with the OH of Thr199 residue. One of the 
sulfonamide/sulfamide oxygen is also involved in a hydrogen interaction with the amide nitrogen of 
Thr199. This coordination pattern, which is typical for all primary sulfonamides/sulfamates, is 
respected also in these cases [16]. The two inhibitors have a similar orientation inside the cavity, but 
23 presents a bended conformation. This could be the result of the strong H-bond involvement of 
ureido-moiety of 23 with Gln92 residue further reinforced by a perpendicular π-stacking between the 
phenyl ring and the His94 at the bottom of the cavity site (Figure 3). 
 
Figure 3. Superimposition of hCA I-17 (purple) and 23 (cyan) adducts. 
 
The 3-(trifluoromethyl)-4-chlorophenyl tail of 17 is involved in hydrophobic interactions with 
Ala135 and Tyr204 whereas the same tail moiety of 23 is slightly retained within the enzymatic cleft 
and makes hydrophobic interactions with Leu131 and Ala135.  
The additional interactions of 23 when compared to 17, within the catalytic cavity site (i.e. π stacking 
and the hydrogen bond interaction with Gln92) are reflected into the kinetic results on the same CA 
isoform. As reported in Table 1 and above discussed, compound 17 is 18.8 fold less effective on hCA 
I when compared to 23 which is bound tighter.  
 
2.4. Effects of Compounds 23 and 24 on Breast Tumor Cell Growth. 
The in vitro obtained results led us to select less investigated sulfamate type inhibitors 23 and 24 
(which are excellent inhibitors of hCA IX with KIs between 0.8-1.3 nM, Table 1) for their effects on 
primary breast tumor HBL100, MDA.MB.231 and MCF7 cell lines in normoxic and hypoxic 
conditions.  
  
  
  
 
Figure 4. The effect of sulfamate type inhibitors 23 and 24 on proliferation of breast cancer cells in 
normoxic and hypoxic conditions. 
HBL100, MDA.MB.231 and MCF7 breast cancer cells (1 x 103)/well, were allowed to adhere for 
24h. Cells were either cultured in normoxia (21% O2), or hypoxia (0.5% O2), for a further 24 h before 
the addition of inhibitors at the concentrations indicated above and cultured in these conditions for a 
further 5 days.  Proliferation was assessed using SRB assays. Results shown mean ± SEM (n=6; 6 
replicates per experiment. 
 
0
20
40
60
80
100
120
0 µM 3 µM 10 µM 30 µM 100 µM%
 C
o
n
tr
o
l 
ce
ll
 n
u
m
b
er
Drug Concentration
HBL100 Normoxia
23
24
0
20
40
60
80
100
120
0 µM 3 µM 10 µM 30 µM 100 µM%
 C
o
n
tr
o
l 
ce
ll
 n
u
m
b
er
Drug concentration
HBL100 Hypoxia
23
24
0
20
40
60
80
100
120
0 µM 3 µM 10 µM 30 µM 100 µM%
 C
o
n
tr
o
l 
ce
ll
 n
u
m
b
er
Drug Concentration
MDA.MB.231 Normoxia
23
24
0
20
40
60
80
100
120
0 µM 3 µM 10 µM 30 µM 100 µM%
 C
o
n
tr
o
l 
ce
ll
 n
u
m
b
er
Drug concentration
MDA.MB.231 Hypoxia
23
24
0
20
40
60
80
100
120
0 µM 3 µM 10 µM 30 µM 100 µM
%
 C
o
n
tr
o
l 
ce
ll
 n
u
m
b
er
Drug Concentration
MCF7 Normoxia
23
24
0
20
40
60
80
100
120
0 µM 3 µM 10 µM 30 µM 100 µM%
 C
o
n
tr
o
l 
ce
ll
 n
u
m
b
er
Drug Concentration
MCF7 Hypoxia 
23
24
 Figure 4 demonstrates that sulfamate type inhibitors 23 and 24 decreased the proliferation of 
all 3 breast cancer cell lines over the time period examined at concentration greater than 10 M. At 
30 M, both sulfamates reduced proliferation by approximately 50%. This occurred regardless of the 
oxygenation status of the cells, with similar concentration responses to both inhibitors, in normoxic 
or hypoxic conditions and in all cell lines studied.  
 
3. Conclusion. 
Herein we reported a series of CAIs obtained by merging the multikinase inhibitor Sorafenib 
with the benzene sulfonamide hCA IX inhibitor SLC-0111. All compounds here share the same tail 
moiety of Sorafenib (i.e. 4-chloro-3-(trifluoromethyl)phenyl ureido group) and were assayed in vitro 
as inhibitors of four hCA isoforms of pharmacological relevance, the cytosolic isoforms hCA I, II 
and VII, and the tumor associated transmembrane isoform hCA IX. Interestingly the in vitro results 
showed a preferential inhibition of the tumor associated isoform with KI values spanning between the 
low to medium nanomolar concentration. We determined the binding modes of compounds 17 and 
23 on the hCA I isoform by means of X-ray crystallographic studies of their adducts with hCA I. 
Despite the canonical binding mode of the sulfonamide and sulfamate for the Zn (II) ion, the 
compounds showed different orientations within the cavity cleft. In particular the latter was involved 
in additional hydrogen a π stacking bondings which resulted in forcing the entire molecule to assume 
a curved conformation. The effects of such additional interactions were also evident from the kinetic 
viewpoint as 23 resulted 18.8 fold more potent in inhibiting the hCA I when compared to 17.  
Two sulfamates 23 and 24 were investigated for their antiproliferative activities on HBL100, 
MDA.MB.231 and MCF7 cell lines at normoxic and hypoxic conditions. Both sulfamates were found 
to decrease proliferation of these breast cancer cell lines at concentrations above 10 M regardless of 
oxygenation status. 
 
 
  
  
4. Experimental Section 
4.1. Chemistry 
All anhydrous solvents and reagents used in this study were purchased from Alfa Aesar, TCI, and 
Sigma-Aldrich. The synthetic reactions involving air- or moisture-sensitive chemicals were carried 
out under a nitrogen atmosphere using dried glassware and syringe techniques in order to transfer the 
solutions. Nuclear magnetic resonance (1 H-, 13C-, and 19F-NMR) spectra were recorded using a 
Bruker Avance III 400 MHz spectrometer using DMSO-d6 as solvent. The chemical shifts are 
reported in parts per million (ppm), and the coupling constants (J) are expressed in Hertz (Hz). The 
splitting patterns are designated as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; brs, broad 
singlet; dd, doublet of doublets. The correct assignment of exchangeable protons (i.e., OH and NH) 
was carried out by means of the addition of D2O. Analytical thin-layer chromatography (TLC) was 
done on Merck silica gel F-254 plates. The HPLC was performed by using a Waters 2690 separation 
module coupled with a photodiode array detector (PDA Waters 996) using a Nova-Pak C18 4 μm 3.9 
mm × 150 mm (Waters) silica-based reverse phase column. The sample was dissolved in 10% 
acetonitrile/H2O and an injection volume of 45 μL. The mobile phase (flow rate 1.0 mL/min) was a 
gradient of H2O + trifluoroacetic acid (TFA) 0.1% (A) and acetonitrile + TFA 0.1% (B), with steps 
as follows: (A%/B%), 0−10 min 90:10, 10−25 min gradient to 60:40, 26:28 min isocratic 20:80, 
29−35 min isocratic 90:10. TFA 0.1% in water as well in acetonitrile was used as counterion. All 
compounds reported here were ≥95% HPLC pure. The solvents used in MS measures were acetone, 
acetonitrile (Chromasolv grade), and mQ water 18 MU. The high resolution mass spectrometry 
(HRMS) analysis was performed with a Thermo Finnigan LTQ Orbitrap mass spectrometer coupled 
with an electrospray ionization source (ESI). Analysis was carried out in positive ion mode [M + H]+, 
and it was used a proper dwell time acquisition to achieve 60,000 units of resolution at full width at 
half maximum (fwhm). Elemental composition of compounds was calculated on the basis of their 
measured accurate masses, accepting only results with an attribution error less than 5 ppm and a not 
integer RDB (double bond/ring equivalents) value. tock solutions of analytes were prepared using 
acetone (1.0 mg mL−1) and stored at 4 °C. Then working solutions of each analyte were prepared by 
dilution of the stock solutions using mQ H2O/ACN 1/1 (v/v) up to a concentration of 1.0 μg mL−1. 
The HRMS analysis was performed by introducing the analyte working solution via syringe pump at 
10 μL min−1.  
4.2. Synthesis of reported compounds 
4.2.1. General synthetic procedure a to synthesis of urea derivatives 12-21 
A solution of amine 1-10 (0.2g, 1 equiv) was treated with 4-chloro-3-(trifluoromethyl)phenyl 
isocyanate 11 (1.0 equv) in dry acetonitrile (3-4 mL). The reaction mixture was stirred at rt until the 
consumption of starting materials (TLC monitoring). Reaction was quenched with H2O to give a 
precipitate that was filtered-off and washed with diethyl ether (3 x 5 mL) and dried under vacuum to 
afford the products 12-21.  
4.2.2. General synthetic procedure b to synthesis of sulfamates 23-24 
A solution of phenols 18-19 (0.2 g, 1.0 equiv) was treated with freshly prepared sulfamoylchloride 
22 (6.0 equiv, portion-wise) in dry DMA at 0 °C. The reaction mixture was warmed to rt and stirred 
for 15 min then quenched with slush. The obtained precipitate was filtered-off, washed with DCM (3 
x 5 mL) and dried under vacuum to afford desired products 23-24. 
4.2.3 Synthesis of 2,5-dioxopyrrolidin-1-yl4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido) 
benzoate (25): A solution of 20 (1.0 g, 1.0 equiv) was treated with NHS (1.5 equiv) at 0 ˚C in dry 
DMF (5.0 ml), followed by addition of EDCI (1.5 equiv). The reaction mixture was stirred until the 
consumption of starting materials (TLC monitoring). The reaction was quenched with H2O to obtain 
a precipitate which was filtered-off, washed with H2O (3 x 5 mL) and dried under vacuum to obtain 
compound 25. 
4.2.4. General synthetic method c for the synthesis of compounds 26-27, 29, 31, 33, 35: A solution 
of amine 5-6, 28, 30, 32 and 34 (50-150 mg, 1.0 equiv) in dry DMF (3-4 mL) was treated with 
activated ester 25 (1.0 equiv), followed by addition of Et3N (2.5 equiv). The reaction mixture was 
stirred until the consumption of the starting materials, then quenched with H2O (2-3 mL) and acidified 
by 1M aqueous solution of HCl. The obtained precipitate was filtered-off, washed with diethyl ether 
(3 x 5 mL) and dried under vacuum to obtain desired products 26-27, 29, 31, 33 and 35. 
4.2.5. 5-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-1,3,4-thiadiazole-2-sulfonamide (12): white 
solid; yield 65%; silica gel TLC Rf 0.35 (MeOH/DCM 10% v/v); mp 242-243 C; δH (400 MHz, 
DMSO-d6) 7.72 (1H, d, J 8.8), 7.83 (1H, m), 8.13 (1H, s), 8.35 (2H, exchange with D2O, SO2NH2), 
9.72 (1H, s, exchange with D2O, NH), 11.88 (1H, s, exchange with D2O, NH); δC (100 MHz, DMSO-
d6) 118.9 (q, 
3JC-F 6), 123.6 (1, 
1JC-F 271), 125.0, 125.1, 127.7 (q, 
2JC-F 30), 133.1, 138.8, 153.3, 164.1, 
164.5; δF (376 MHz, DMSO-d6) -61.5; m/z (ESI negative) 399.9 [M-H]-. 
4.2.6. 4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)benzenesulfonamide (13): White solid, yield 
60%; silica gel TLC Rf 0.55 (MeOH/DCM 20% v/v); mp 260-261 C; δH (400 MHz, DMSO-d6) 7.26 
(2H, s, exchange with D2O, SO2NH2), 7.66 (4H, m), 7.77 (2H, d, J 8.0), 8.16 (1H, m), 9.28 (1H, s, 
exchange with D2O, NH), 9.31 (1H, s, exchange with D2O, NH); δC (100 MHz, DMSO-d6) 117.9 (q, 
3JC-F6), 118.9, 123.7 (q, 
4JC-F 2), 123.8 (q, 
1JC-F 271.3), 124.2, 127.7 (q, 
2JC-F 30.4), 127.8, 133.0, 
138.3, 139.9, 143.3, 153.2; δF (376 MHz, DMSO-d6) -61.4; m/z (ESI negative) 392.0 [M-H]-. 
4.2.7. 3-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)benzenesulfonamide (14): White solid, yield 
76%; silica gel TLC Rf 0.45 (MeOH/DCM 10% v/v); mp 245-246 ºC; δH (400 MHz, DMSO-d6) 7.40 
(2H, s, exchange with D2O, SO2NH2), 7.51 (2H, m), 7.60 (1H, dt, J 2.0, 7.6), 7.68 (2H, m), 8.12 (1H, 
m), 8.17 (1H, d, J 2.0), 9.23 (1H, s, exchange with D2O, NH), 9.25 (1H, s, exchange with D2O, NH); 
δC (100 MHz, DMSO-d6) 116.5, 117.9 (q, 3JC-F 22), 120.3, 122.5, 123.6 (q, 4JC-F 2), 123.8 (q, 1JC-F 
271), 124.2, 127.7 (q, 3JC-F 30), 130.4, 132.9, 140.1, 140.7, 145.7, 153.3; δF (376 MHz, DMSO-d6) -
61.5; m/z (ESI positive) 392.0 [M-H]-. 
4.2.8. 3-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-4-hydroxybenzenesulfonamide (15): White 
solid, yield 62%; silica gel TLC Rf 0.12 (MeOH/DCM 10% v/v); mp 254-255 ºC; δH (400 MHz, 
DMSO-d6) 6.99 (1H, d, J 8.4), 7.16 (2H, s, exchange with D2O, SO2NH2), 7.36 (1H, dd, J 2.4, 8.4), 
7.60 (1H, dd, J 2.0, 8.8), 7.66 (1H, d, J 8.8), 8.20 (1H, d, J 2.0), 8.48 (1H, s, exchange with D2O, 
NH), 8.66 (1H, d, J 2.4), 9.89 (1H, s, exchange with D2O, NH), 10.96 (1H, s, exchange with D2O, 
OH); δC (100 MHz, DMSO-d6) 114.7, 117.1, 117.3 (q, 3JC-F 6), 121.4, 123.2 (q, 1JC-F 273), 123.4 (q, 
4JC-F 2), 123.6, 127.8 (q, 
2JC-F 30), 128.3, 133.1, 135.9, 140.2, 149.5, 153.1; δF (376 MHz, DMSO-d6) 
-61.5; m/z (ESI negative) 408.0 [M-H]-. 
4.2.9. 4-((3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)methyl)benzenesulfonamide (16): White 
solid, yield 20%; mp 158-159 C; δH (400 MHz, DMSO-d6) 4.40 (2H, d, J 5.6), 7.00 (1H, t, J 5.6, 
exchange with D2O, NH), 7.34 (2H, s, exchange with D2O, SO2NH2), 7.50 (2H, d, J 8.4), 7.58 (1H, 
d, J 8.8), 7.64 (1H, dd, J 2.4, 8.8), 7.81 (2H, d, J 8.4), 8.11 (1H, d, J 2.4), 9.25 (1H, s, exchange with 
D2O, NH); δC (100 MHz, DMSO-d6) 43.4, 117.1 (q, 3JC-F 6), 122.4 (q, 4JC-F 2), 123.2, 123.8 (q, 1JC-F 
271), 126.7, 127.6 (q, 2JC-F 30), 128.2, 132.7, 141.0, 143.5, 145.2, 155.9; δF (376 MHz, DMSO-d6) -
61.4; m/z (ESI positive) 452.0 [M+HCOO]-. 
4.2.10. 4-(2-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)ethyl)benzenesulfonamide (17): White 
solid, yield 78%; silica gel TLC Rf 0.67 (MeOH/DCM 20% v/v); mp 229-230 C; δH (400 MHz, 
DMSO-d6) 2.88 (2H, t, J 6.8), 3.41 (2H, q, J 6.8), 6.39 (1H, t, J 6.8, exchange with D2O, NH), 7.33 
(2H, s, exchange with D2O, SO2NH2), 7.46 (2H, d, J 8.2), 7.58 (2H, m), 7.79 (2H, d, J 8.2), 8.10 (1H, 
m), 9.03 (1H, s, exchange with D2O, NH); δC (100 MHz, DMSO-d6) 36,3, 41.3, 117.1 (q, 3JC-F 6), 
122.4 (q, 4JC-F 2), 123.2, 123.8 (q, 
1JC-F 271), 126.7, 127.6 (q, 
2JC-F 30), 130.1, 132.7, 141.0, 143.1, 
144.7, 155.8; δF (376 MHz, DMSO-d6) -61.4; m/z (ESI positive) 422.0 [M+H]+. 
4.2.11. 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-hydroxyphenyl)urea (18): White solid, yield 
55%; silica gel TLC Rf 0.33 (MeOH/DCM 10% v/v); δH (400 MHz, DMSO-d6) 6.73 (2H, d, J 8.8), 
7.26 (2H, d, J 8.8), 7.64 (2H, m), 8.13 (1H, d, J 2.4), 8.51 (1H, exchange with D2O, NH), 9.05 (1H, 
exchange with D2O, NH), 9.15 (1H, s, exchange with D2O, OH); δC (100 MHz, DMSO-d6) 116.2, 
117.5 (q, 3JC-F 6), 122.0, 122.9 (q, 
4JC-F 2), 123.7, 123.8 (q, 
1JC-F 271), 127.8 (q, 
2JC-F 30), 131.5, 132.8, 
140.6, 153.6, 154.0; δF (376 MHz, DMSO-d6) -61.5. 
4.2.12. 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(3-hydroxyphenyl)urea (19): White solid, yield 
60%; silica gel TLC Rf 0.47 (MeOH/DCM 10% v/v); δH (400 MHz, DMSO-d6) 6.44 (1H, m), 6.84 
(1H, m), 7.08 (2H, m), 7.64 (1H, d, J 1.2), 8.15 (1H, t, J 1.2), 8.75 (1H, exchange with D2O, NH), 
9.10 (1H, exchange with D2O, NH), 9.37 (1H, s, exchange with D2O, OH); δC (100 MHz, DMSO-d6) 
106.6, 110.2, 110.4, 117.6 (q, 3JC-F 6), 123.1 (q, 
4JC-F 2), 123.7 (q, 
1JC-F 271), 123.9, 127.5 (q, 
2JC-F 
30), 130.4, 132.9, 140.3, 141.1, 153.2, 158.7; δF (376 MHz, DMSO-d6) -61.5. 
4.2.13. 4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)benzoic acid (20): White solid, yield 77%; 
silica gel TLC Rf  0.45 (EtOAc/n-hexane 80% v/v); δH (400 MHz, DMSO-d6) 7.62 (2H, d, J 8.8), 7.68 
(2H, m), 7.91 (2H, d, J 8.8), 8.15 (1H, m), 9.26 (1H, exchange with D2O, NH), 9.30 (1H, s, exchange 
with D2O, NH), 12.68 (1H, s, exchange with D2O, COOH); δC (100 MHz, DMSO-d6) 117.9 (q, 3JC-F 
6), 118.6, 123.6 (q, 4JC-F 2), 123.7 (q, 
1JC-F 271), 124.2, 125.1, 127.7 (q, 
2JC-F 30), 131.5, 133.0, 140.0, 
144.5, 153.1, 167.9; δF (376 MHz, DMSO-d6) -61.5. 
4.2.14. 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(4-methyl-2-oxo-2H-chromen-7-yl)urea (21): 
White solid; yield 70%; mp>300C; δH (400 MHz, DMSO-d6) 2.44 (3H, s), 6.27 (1H, s), 7.40 (1H, 
d, J 8.6), 7.64-7.74 (4H, m), 8.13 (1H, m), 9.39 (1H, s, exchange with D2O, NH), 9.42 (1H, s, 
exchange with D2O, NH); δC (100 MHz, DMSO-d6) 18.8, 105.6, 112.6, 115.0, 115.4, 117.8 (q, 3JC-F 
6), 123.5 (q, 4JC-F 2), 123.6 (q, 
1JC-F 270), 124.2, 126.7, 127.7 (q, 
2JC-F 30), 132.9, 139.8, 143.8, 153.0, 
154.0, 154.8, 160.9; δF (376 MHz, DMSO-d6) -61.5; m/z (ESI negative) 395.0 [M-H]-. 
4.2.15. 4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenyl sulfamate (23): White solid, yield 
77%; silica gel TLC Rf 0.70 (MeOH/DCM 10% v/v); mp 175-176C (dec); δH (400 MHz, DMSO-d6) 
7.24 (2H, d, J 9.0), 7.55 (2H, d, J 9.0), 7.66 (2H, m), 7.95 (2H, s, exchange with D2O, SO2NH2), 8.14 
(1H, d, J 2.2), 9.00 (1H, exchange with D2O, NH), 9.21 (1H, exchange with D2O, NH);δC (100 MHz, 
DMSO-d6) 117.7 (q, 
3JC-F 6), 120.6, 123.3 (q, 
4JC-F 3), 123.6, 123.8 (q, 
1JC-F 271), 124.0, 127.7 (q, 
2JC-F 30), 132.9, 138.6, 140.2, 145.9, 153.4; m/z (ESI negative) 408.0 [M-H]
-. 
4.2.16. 3-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenyl sulfamate (24): White solid, yield 
65%; silica gel TLC Rf 0.55 (MeOH/DCM 10% v/v); mp 190-191C (dec); δH (400 MHz, DMSO-d6) 
6.95 (1H, m), 7.39 (2H, m), 7.57 (1H, m), 7.67 (2H, m), 8.03 (2H, exchange with D2O, SO2NH2), 
8.15 (1H, d, J 2.0), 9.11 (1H, exchange with D2O, NH), 9.21 (1H, s, exchange with D2O, NH);δC (100 
MHz, DMSO-d6) 113.2, 116.6, 117.4, 117.8 (q, 
3JC-F 6), 123.4 (q, 
4JC-F 2), 123.7 (q, 
1JC-F 271), 124.1, 
127.7 (q, 2JC-F 30), 130.7, 132.9, 140.1, 141.4, 151.4, 153.2; δF (376 MHz, DMSO-d6) -61.5; m/z (ESI 
negative) 408.0 [M-H]-. 
4.2.17. 2,5-dioxopyrrolidin-1-yl 4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)benzoate (25): 
White solid; yield 92%; δH (400 MHz, DMSO-d6) 2.92 (4H, s), 7.70 (2H, m), 7.77 (2H, d, J 9.0), 7.99 
(1H, s), 8.07 ( 2H, d, J 9.0), 8.17 (1H, d, J 2.2), 9.45 (1H, exchange with D2O, NH), 9.57 (1H, s, 
exchange with D2O, NH); δC (100 MHz, DMSO-d6) 26.4, 118.1, 118.1 (q, 3JC-F 6), 119.0, 123.8 (q, 
4JC-F 2), 123.7 (q, 
1JC-F 271), 124.4, 127.7 (q, 
2JC-F 30), 132.4, 132.9, 139.7, 146.8, 152.9, 162.2, 
171.3; δF (376 MHz, DMSO-d6) -61.5. 
4.2.18. 4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-N-(4-sulfamoylbenzyl)benzamide (26): 
White solid; yield 60%; silica gel TLC Rf 0.26 (MeOH/DCM 10% v/v); mp195-196 C; δH (400 MHz, 
DMSO-d6) 4.56 (2H, d, J 6.0), 7.35 (2H, s, exchange with D2O, SO2NH2), 7.52 (2H, d, J 8.3), 7.59 
(2H, d, J 8.8), 7.68 (2H, m), 7.81 (2H, d, J 8.3), 7.90 (2H, d, J 8.8), 8.16 (1H, m), 9.04 (1H, t, J 6.0, 
exchange with D2O, NH), 9.18 (1H, s, exchange with D2O, NH), 9.30 (1H, s, exchange with D2O, 
NH); δC (100 MHz, DMSO-d6) 43.2, 117.8 (q, 3JC-F 6), 118.5, 123.5 (q, 4JC-F 2), 123.7 (q, 1JC-F 270), 
124.2, 126.6, 127.7 (q, 2JC-F 30), 128.4, 128.6, 129.2, 133.0, 140.1, 143.1, 143.5, 144.9, 153.2, 166.8; 
δF (376 MHz, DMSO-d6) -61.5; m/z (ESI negative) 525.1 [M-H]-. 
4.2.19. 4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-N-(4-sulfamoylphenethyl)benzamide (27): 
White solid; yield 62%; silica gel TLC Rf 0.22 (EtOAc/n-hexane 80% v/v); mp 269-270 C; δH (400 
MHz, DMSO-d6) 2.96 (2H, t, J 7.2), 3.54 (2H, q, J 7.2), 7.32 (2H, s, exchange with D2O, SO2NH2), 
7.47 (2H, d, J 8.4), 7.57 (2H, d, J 8.8), 7.67 (2H, m), 7.80 (4H, m), 8.15 (1H, m), 8.49 (1H, t, J 7.2, 
exchange with D2O, NH), 9.14 (1H, s, exchange with D2O, NH), 9.29 (1H, s, exchange with D2O, 
NH);δC (100 MHz, DMSO-d6) 35.8, 41.3, 117.8 (q, 3JC-F 6), 118.5, 123.5 (q, 4JC-F 2), 123.7 (q, 1JC-F 
270), 124.1, 126.6, 127.7 (q, 2JC-F 30), 129.0, 129.0, 130.1, 133.0, 140.1, 142.8, 143.0, 144.8, 153.2, 
166.7; δF (376 MHz, DMSO-d6) -61.5; m/z (ESI negative) 539.1 [M-H]-. 
4.2.20. 4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-N-(6-(4-
sulfamoylphenoxy)hexyl)benzamide (29): White solid, yield 64%; silica gel TLC Rf 0.25 
(MeOH/DCM 10% v/v); mp 231-232 C; δH (400 MHz, DMSO-d6) 2.03 (2H, pent, J 6.5), 3.45 (2H, 
q, J 6.5), 4.15 (2H, t, J 6.5), 7.12 (2H, d, J 8.9), 7.23 (2H, s, exchange with D2O, SO2NH2), 7.57 (2H, 
d, J 8.8), 7.67 (2H, m), 7.78 (2H, d, J 8.9), 7.84 (2H, d, J 8.8), 8.15 (1H, m), 8.46 (1H, t, J 6.5, 
exchange with D2O, NH), 9.14 (1H, s, exchange with D2O, NH), 9.27 (1H, s, exchange with D2O, 
NH); δC (100 MHz, DMSO-d6) 29.8, 37.1, 66.8, 115.4, 117.8 (q, 3JC-F 6), 118.4, 123.5 (q, 4JC-F 2), 
123.7 (q, 1JC-F 270), 124.1, 127.7 (q, 
2JC-F 30), 127.8, 128.6, 129.0, 129.1, 132.9, 137.0, 140.1, 142.8, 
153.2, 162.0, 166.8; δF (376 MHz, DMSO-d6) -61.5; m/z (ESI negative) 569.1 [M-H]-. 
4.2.21. 4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-N-(6-(4-
sulfamoylphenoxy)hexyl)benzamide (31): White solid; yield 55%; mp 237-238C; δH (400 MHz, 
DMSO-d6) 1.44 (4H, m), 1.58 (2H, pent, J 7.0), 1.77 (2H, pent, J 7),3.28 (2H, q, J 7.0), 4.08 (2H, t, 
J 7.0), 7.10 (2H, d, J 8.8), 7.23 (2H, s, exchange with D2O, SO2NH2), 7.57 (2H, d, J 8.6), 7.66 (2H, 
m), 7.78 (2H, d, J 8.8), 7.83 (2H, d, J 8.6), 8.16 (1H, s), 8.36 (1H, t, J 7.0, exchange with D2O, NH), 
9.15 (1H, s, exchange with D2O, NH), 9.30 (1H, s, exchange with D2O, NH); δC (100 MHz, DMSO-
d6) 26.2, 27.2, 29.4, 30.1, 68.8, 115.3,117.8 (q, 
3JC-F 6), 118.4, 123.5 (q, 
4JC-F 2), 123.7 (q, 
1JC-F 270), 
124.1, 127.7 (q, 2JC-F 30), 127.8, 128.6, 129.0, 129.2, 133.0, 136.9, 140.1, 142.7, 153.2, 162.0, 166.5; 
δF (376 MHz, DMSO-d6) -61.5; m/z (ESI negative) 611.2 [M-H]-. 
4.2.22. 4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-N-(2-((2-oxo-2H-chromen-7-yl)oxy)ethyl) 
benzamide (33): White solid; yield 35%; mp 217-218 C; δH (400 MHz, DMSO-d6) 3.67 (2H, q, J 
5.6), 4.26 (2H, t, J 5.6), 6.32 (1H, d, J 9.5), 7.00 (1H, dd, J 2.4, 8.6), 7.08 (1H, d, J 2.4), 7.57 (2H, d, 
J 8.8), 7.66 (3H, m), 7.86 (2H, d, J 8.8), 8.02 (1H, d, J 9.5), 8.15 (1H, m), 8.65 (1H, t, J 5.6, exchange 
with D2O, NH), 9.21 (1H, s, exchange with D2O, NH), 9.36 (1H, s, exchange with D2O, NH); δC (100 
MHz, DMSO-d6) 39.5, 67.8, 102.2, 113.4, 113.5, 113.7, 117.7 (q, 
3JC-F 6), 118.4, 123.5 (q, 
4JC-F 2), 
123.8 (q, 1JC-F 270), 124.1, 127.6 (q, 
2JC-F 30), 127.8, 128.6, 128.6, 129.2, 130.5, 133.0, 140.1, 143.1, 
145.3, 153.2, 156.4, 161.3, 162.6, 167.0; δF (376 MHz, DMSO-d6) -61.5; m/z (ESI negative) 544.1 
[M-H]-. 
4.2.23. 4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-N-(2-((2-oxo-2H-chromen-6-yl)oxy)ethyl) 
benzamide (35): White solid, yield 42%; mp 219-220 C; δH (400 MHz, DMSO-d6) 3.68 (2H, q, J 
5.6), 4.20 (2H, t, J 5.6), 6.53 (1H, d, J 9.6), 7.27 (1H, dd, J 2.4, 8.8), 7.38 (2H, m), 7.58 (2H, d, J 8.8), 
7.67 (2H, m), 7.86 (2H, d, J 8.8), 8.04 (1H, d, J 9.6), 8.15 (1H, m), 8.66 (1H, t, J 5.6,exchange with 
D2O, NH), 9.29 (1H, s, exchange with D2O, NH), 9.45 (1H, s, exchange with D2O, NH); δC (100 
MHz, DMSO-d6) 39.7, 67.7, 112.5, 117.5, 117.7 (q, 
3JC-F 6), 118.3, 118.4, 120.2, 120.8, 123.4 (q, 
4JC-
F 2), 124.0, 124.2 (q, 
1JC-F 270), 127.6 (q, 
2JC-F 30), 128.6, 129.2, 133.0, 140.1, 143.0, 145.0, 
148.8,153.2, 155.7, 161.1, 167.0 ; δF (376 MHz, DMSO-d6) -61.5; m/z (ESI negative) 544.1 [M-H]-. 
4.3. CA inhibition 
An Applied Photophysics stopped-flow instrument has been used for assaying the CA catalyzed CO2 
hydration activity [52]. Phenol red (at a concentration of 0.2 mM) has been used as indicator, working 
at the absorbance maximum of 557 nm, with 20 mM Hepes (pH 7.5) as buffer, and 20 mM Na2SO4 
(for maintaining constant the ionic strength), following the initial rates of the CA-catalyzed CO2 
hydration reaction for a period of 10-100 s. The CO2 concentrations ranged from 1.7 to 17 mM for 
the determination of the kinetic parameters and inhibition constants. For each inhibitor at least six 
traces of the initial 5-10% of the reaction have been used for determining the initial velocity. The 
uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. 
Stock solutions of inhibitor (0.1 mM) were prepared in distilled-deionized water and dilutions up to 
0.01 nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were preincubated 
together at room temperature (15 min) prior to assay, in order to allow for the formation of the E-I 
complex. Data from Table 1 were obtained after 15 minutes incubation of enzyme and inhibitor, as 
for the sulfonamides reported earlier [5,42,55,56]. The inhibition constants were obtained by non-
linear least-squares methods using PRISM 3 and the Cheng-Prusoff equation, as reported earlier 
[5,42,55,56] and represent the mean from at least three different determinations. All CA isoforms 
were recombinant ones obtained in-house as reported earlier [5,42,55,56]. 
4.4. Co-crystallization and X-ray data collection 
Crystals of hCA I complexed with compounds 17 and 23 were obtained using the sitting drop vapor 
diffusion method. 2 µl of 10 mg/ml solution of hCA I in Tris-HCl 20 mM pH 9.0 were mixed with 2 
µl of a solution of 28-31% PEG4000, 0.2 M Sodium acetate, 0.1 M Tris pH 8.5-9.0 and were 
equilibrated against the same solution at 296 K. Crystals of the protein grew in fifteen days. 
Afterwards hCAI crystals were soaked in 5mM inhibitor solutions for 3 days. 
The crystals were flash-frozen at 100 K using a solution obtained by adding 15% (v/v) glycerol to the 
mother liquor solution as cryoprotectant. Data on crystals of the complexes were collected using 
synchrotron radiation at the ID30A-1 beamline at ESRF (Grenoble, France) with a wavelength of 
0.966 Å and a PILATUS3 2M Dectris CCD detector. Data were integrated and scaled using the 
program XDS [57].Data processing statistics are shown in Supporting Information Table S1. 
4.4.1. Structure determination 
The crystal structure of hCA I (PDB accession code 1JV0) without solvent molecules and other 
heteroatoms was used to obtain initial phases of the structures using Refmac5 [58]. 5% of the unique 
reflections were selected randomly and excluded from the refinement data set for the purpose of Rfree 
calculations. The initial |Fo - Fc| difference electron density map unambiguously showed the inhibitor 
molecules. Atomic models for inhibitors were calculated and energy minimized using the program 
JLigand 1.0.40 [59]. Refinements proceeded using normal protocols of positional, isotropic atomic 
displacement parameters alternating with manual building of the models using COOT [60]. Solvent 
molecules were introduced automatically using the program ARP [61]. The quality of the final models 
were assessed with COOT and RAMPAGE [62]. Crystal parameters and refinement data are 
summarized in Table S1 in the Supporting information. Atomic coordinates were deposited in the 
Protein Data Bank (PDB accession code: 6I0L and 6I0J). Graphical representations were generated 
with Chimera [63]. 
4.5. Cell Lines and Culture 
The breast cancer cell lines, HBL100, MCF7 and MDA.MB.231 were cultured in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10% foetal bovine serum, 100 U/ml penicillin 
and 100 μg/ml streptomycin in 21% O2. Hypoxic cells were grown at 0.5% O2 in a Don Whitley H35 
Hypoxystation. All cell lines used were tested and authenticated using STR profiling by Public Health 
England, Porton Down, Salisbury, UK. 
4.5.1. Sulforhodamine B assay 
Cells (1 x 103/well) were seeded into 96-well flat-bottomed plates and incubated for 48 h before the 
sulfamates were added using concentrations between 0 – 300 M. After 5 days treatment, plates were 
fixed by the addition of 50 μl 25% trichloroacetic acid solution per well for 1 h at 4 °C. Plates were 
washed with H2O and air dried before the addition of 50 μl 0.4% sulforhodamine B solution in 1% 
acetic acid for 30 min. Plates were washed in 1% acetic acid and air dried before the addition of 150 μl 
10 mM Tris solution (pH 10.5). After 30 min, the absorbance of each well was measured at 540 nm 
on a BP900 biohit plate reader. 
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Table 1. Summary of Data Collection and Atomic Model Refinement Statistics.1 
 17 23 
PDB ID 6I0L 6I0J 
Wavelength (Å) 0.966 0.966 
Space Group P 21 21 21 P 21 21 21 
Unit cell (a,b,c) (Å) 62.46, 70.45, 121.56 62.45, 71.26, 121 
Limiting resolution (Å) 1.40 1.35 
Unique reflections 105401 (16390) 118885 (18527) 
Rsym (%)
 
4.5 (215.5) 5,1 (342.8) 
Rmeas (%) 5.1 (224.1) 5.7 (336.1) 
Redundancy 3.46 (3.39) 3.57 (3.45) 
Completeness overall 
(%) 
98.6 (96.1) 99,0 (96.6) 
<I/(I)> 11.88 (0.58) 10.86 (0.35) 
CC (1/2) 99.9 (30.2) 99.9 (12.3) 
Refinement statistics   
Resolution range (Å) 28.6-1.4 28.6-1.35 
Unique reflections/ 
working/free 
99944 / 4859 112540 / 5325 
Rfactor (%) 20.40 19.68 
Rfree(%) 23.70 23.25 
No. of protein atoms 4050 4051 
No. of water molecules 504 581 
No. of heterogen atoms 64 80 
r.m.s.d. length(Å) 0.0118 0.0112 
r.m.s.d. angles (°) 1.449 1.4543 
Ramachandran 
statistics (%) 
  
Most favored 97.5 97.5 
additionally allowed 2.5 2.5 
outlier regions 0 0 
Average B factor (Å2)   
All atoms 29.798 26.494 
inhibitors 49.991 26.436 
solvent 39.805 37.992 
1
Values in parentheses are for the highest resolution shell. 
